National Research (NRC) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 May, 2026Executive summary
Q1 2026 achieved record Total Recurring Contract Value (TRCV) of $152.1 million, up 13% year-over-year, with revenue growth for the first time since 2023, reaching $34.8 million.
New sales bookings surged over 200% year-over-year, driven by the largest multi-year deal in company history, with customer retention at multi-year highs.
Gross retention rate reached its highest level in over seven years, reflecting improved customer engagement and product enhancements.
Operating income declined 35% to $5.6 million due to increased executive compensation and technology investments.
The company is focused on expanding its platform, driving actionable insights, and supporting healthcare organizations in a challenging market.
Financial highlights
Q1 revenue was $34.8 million, up 4% year-over-year, with TRCV at $152.1 million, up 13% year-over-year and 5% sequentially.
Adjusted EBITDA was $9.4 million (27% margin), up 230 basis points sequentially but down from 30.8% in the prior year.
Adjusted net income was $4.6 million, with adjusted EPS of $0.21, up $0.05 sequentially.
Free cash flow rose nearly 50% year-over-year to $5.3 million ($0.24 per share), with free cash flow margin at 15.4%.
Net income fell to $3.2 million from $5.8 million year-over-year, with diluted EPS at $0.14.
Outlook and guidance
The landmark multi-year deal will be implemented in two phases, with Phase I (Experience platform) going live in Q3 2026 and Phase II (Enablement platform) in Q3 2027.
Near-term margin expansion will be limited by implementation costs and a $9.4 million Q2 expense from executive equity award amendments, but margins are expected to expand in Q3 and beyond.
Long-term EBITDA margin is targeted to return to the low 30s in the midterm and potentially mid-30s longer term, assuming mid- to high single-digit top-line growth.
Management expects existing liquidity and cash flows to be sufficient for foreseeable capital and debt needs.
Latest events from National Research
- Key votes include director elections, auditor ratification, and major governance amendments.NRC
Proxy filing8 May 2026 - Proxy seeks approval for board declassification, governance reforms, and executive compensation changes.NRC
Proxy filing8 May 2026 - Proxy seeks approval for board declassification, governance reforms, and executive pay alignment.NRC
Proxy filing29 Apr 2026 - Q4 2025 revenue rose 2%, TRCV up 8% YoY, and a $0.16 dividend was declared.NRC
Q4 20253 Feb 2026 - Huey AI enhances healthcare experience management with tailored, ethical, and privacy-focused solutions.NRC
Status Update3 Feb 2026 - Timely, representative feedback and focus on key drivers accelerate patient experience improvement.NRC
Status update2 Feb 2026 - Significant CAHPS and HCAHPS survey changes and reporting updates are set for 2025–2030.NRC
Status Update22 Jan 2026 - AI and digital tools can transform healthcare if implemented transparently and with human well-being at the core.NRC
Status Update13 Jan 2026 - 2025 proxy seeks approval for director elections, auditor, say-on-pay, and new incentive plan.NRC
Proxy Filing2 Dec 2025